Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
aDC1-Based Treatment and Chemokine Modulation in PD-1/PD-L1 Resistant Melanoma
NCT04093323Phase 2Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Nov 2024
- Primary completion
- Apr 2025
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of alpha-type-1-polarized dendritic cell vaccine in melanoma, sponsored by Roswell Park Comprehensive Cancer Center. Started Nov 2024; status: terminated.
02
Drugs
alpha-type-1-polarized dendritic cell vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04093323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04093323.